A Scoping Review on Body Fluid Biomarkers for Prognosis and Disease Activity in Patients with Multiple Sclerosis

Overview

Journal J Pers Med

Date 2022 Sep 23

PMID 36143216

Authors

Nadia Barizzone

Maurizio Leone

Alessandro Pizzino

Ingrid Kockum

Filippo Martinelli-Boneschi

Sandra DAlfonso

Affiliations

Soon will be listed here.

Abstract

Multiple sclerosis (MS) is a complex demyelinating disease of the central nervous system, presenting with different clinical forms, including clinically isolated syndrome (CIS), which is a first clinical episode suggestive of demyelination. Several molecules have been proposed as prognostic biomarkers in MS. We aimed to perform a scoping review of the potential use of prognostic biomarkers in MS clinical practice. We searched MEDLINE up to 25 November 2021 for review articles assessing body fluid biomarkers for prognostic purposes, including any type of biomarkers, cell types and tissues. Original articles were obtained to confirm and detail the data reported by the review authors. We evaluated the reliability of the biomarkers based on the sample size used by various studies. Fifty-two review articles were included. We identified 110 molecules proposed as prognostic biomarkers. Only six studies had an adequate sample size to explore the risk of conversion from CIS to MS. These confirm the role of oligoclonal bands, immunoglobulin free light chain and chitinase CHI3L1 in CSF and of serum vitamin D in the prediction of conversion from CIS to clinically definite MS. Other prognostic markers are not yet explored in adequately powered samples. Serum and CSF levels of neurofilaments represent a promising biomarker.

Citing Articles

Neuroimaging to monitor worsening of multiple sclerosis: advances supported by the grant for multiple sclerosis innovation.

Oh J, Airas L, Harrison D, Jarvinen E, Livingston T, Lanker S Front Neurol. 2023; 14:1319869.

PMID: 38107636 PMC: 10722910. DOI: 10.3389/fneur.2023.1319869.

Therapeutic Plasma Exchange and Multiple Sclerosis Dysregulations: Focus on the Removal of Pathogenic Circulatory Factors and Altering Nerve Growth Factor and Sphingosine-1-Phosphate Plasma Levels.

Tonev D, Momchilova A Curr Issues Mol Biol. 2023; 45(10):7749-7774.

PMID: 37886933 PMC: 10605592. DOI: 10.3390/cimb45100489.

The myth of brain damage: no change of neurofilament light chain during transient cognitive side-effects of ECT.

Besse M, Belz M, Bartels C, Herzig B, Wiltfang J, Zilles-Wegner D Eur Arch Psychiatry Clin Neurosci. 2023; 274(5):1187-1195.

PMID: 37656172 PMC: 11226499. DOI: 10.1007/s00406-023-01686-8.

Biomarkers in autoimmune diseases of the central nervous system.

Zhang F, Gao X, Liu J, Zhang C Front Immunol. 2023; 14:1111719.

PMID: 37090723 PMC: 10113662. DOI: 10.3389/fimmu.2023.1111719.

Two Single Nucleotide Polymorphisms in the Purinergic Receptor Gene Are Associated with Disease Severity in Multiple Sclerosis.

Guerini F, Agliardi C, Bolognesi E, Zanzottera M, Caputo D, Pasanisi M Int J Mol Sci. 2022; 23(23).

PMID: 36499708 PMC: 9736555. DOI: 10.3390/ijms232315381.

References

Martinelli V, Dalla Costa G, Colombo B, Dalla Libera D, Rubinacci A, Filippi M . Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler. 2013; 20(2):147-55. DOI: 10.1177/1352458513494959. View

Verderio C, Muzio L, Turola E, Bergami A, Novellino L, Ruffini F . Myeloid microvesicles are a marker and therapeutic target for neuroinflammation. Ann Neurol. 2012; 72(4):610-24. DOI: 10.1002/ana.23627. View

Barro C, Leocani L, Leppert D, Comi G, Kappos L, Kuhle J . Fluid biomarker and electrophysiological outcome measures for progressive MS trials. Mult Scler. 2017; 23(12):1600-1613. DOI: 10.1177/1352458517732844. View

Teunissen C, Sombekke M, van Winsen L, Killestein J, Barkhof F, Polman C . Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. Mult Scler. 2012; 18(8):1092-8. DOI: 10.1177/1352458511433306. View

Rifai N, Christenson R, Gelman B, Silverman L . Changes in cerebrospinal fluid IgG and apolipoprotein E indices in patients with multiple sclerosis during demyelination and remyelination. Clin Chem. 1987; 33(7):1155-7. View

Pukoli D, Polyak H, Rajda C, Vecsei L . Kynurenines and Neurofilament Light Chain in Multiple Sclerosis. Front Neurosci. 2021; 15:658202. PMC: 8185147. DOI: 10.3389/fnins.2021.658202. View

Kacperska M, Jastrzebski K, Tomasik B, Walenczak J, Konarska-Krol M, Glabinski A . Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study. J Mol Neurosci. 2014; 56(1):154-63. PMC: 4382531. DOI: 10.1007/s12031-014-0476-3. View

Martinez-Yelamos A, Rovira A, Sanchez-Valle R, Martinez-Yelamos S, Tintore M, Blanco Y . CSF 14-3-3 protein assay and MRI as prognostic markers in patients with a clinically isolated syndrome suggestive of MS. J Neurol. 2004; 251(10):1278-9. DOI: 10.1007/s00415-004-0524-y. View

Karussis D . The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014; 48-49:134-42. DOI: 10.1016/j.jaut.2014.01.022. View

10.

Fialova L, Bartos A, Soukupova J, Svarcova J, Ridzon P, Malbohan I . Synergy of serum and cerebrospinal fluid antibodies against axonal cytoskeletal proteins in patients with different neurological diseases. Folia Biol (Praha). 2009; 55(1):23-6. View

11.

Durante L, Zaaraoui W, Rico A, Crespy L, Wybrecht D, Faivre A . Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler. 2011; 18(5):587-91. DOI: 10.1177/1352458511424589. View

12.

Haghikia A, Haghikia A, Hellwig K, Baraniskin A, Holzmann A, Decard B . Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology. 2012; 79(22):2166-70. DOI: 10.1212/WNL.0b013e3182759621. View

13.

Weinstock-Guttman B, Zivadinov R, Horakova D, Havrdova E, Qu J, Shyh G . Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry. 2013; 84(11):1186-91. DOI: 10.1136/jnnp-2012-304740. View

14.

Voortman M, Stojakovic T, Pirpamer L, Jehna M, Langkammer C, Scharnagl H . Prognostic value of free light chains lambda and kappa in early multiple sclerosis. Mult Scler. 2016; 23(11):1496-1505. DOI: 10.1177/1352458516681503. View

15.

Tintore M, Rovira A, Rio J, Tur C, Pelayo R, Nos C . Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology. 2007; 70(13 Pt 2):1079-83. DOI: 10.1212/01.wnl.0000280576.73609.c6. View

16.

Miller E, Walczak A, Saluk J, Ponczek M, Majsterek I . Oxidative modification of patient's plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem. 2011; 45(1-2):26-30. DOI: 10.1016/j.clinbiochem.2011.09.021. View

17.

Khalil M, Enzinger C, Langkammer C, Ropele S, Mader A, Trentini A . CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler. 2012; 19(4):436-42. PMC: 3652709. DOI: 10.1177/1352458512458010. View

18.

Geraci F, Ragonese P, Barreca M, Aliotta E, Mazzola M, Realmuto S . Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid. Front Cell Neurosci. 2018; 12:418. PMC: 6249419. DOI: 10.3389/fncel.2018.00418. View

19.

Bittner S, Bobak N, Herrmann A, Gobel K, Meuth P, Hohn K . Upregulation of K2P5.1 potassium channels in multiple sclerosis. Ann Neurol. 2010; 68(1):58-69. DOI: 10.1002/ana.22010. View

20.

DAmbrosio A, Pontecorvo S, Colasanti T, Zamboni S, Francia A, Margutti P . Peripheral blood biomarkers in multiple sclerosis. Autoimmun Rev. 2015; 14(12):1097-110. DOI: 10.1016/j.autrev.2015.07.014. View